Goldman Sachs analyst Irma Sgarz downgrades Vitru (NASDAQ:VTRU) from Buy to Neutral.
Exicure, Inc. Announces Restructuring Including 66% Workforce Reduction And Exploration Of Divestiture Opportunities For Clinical-Stage Asset In Immuno-Oncology And Preclinical Candidates
Upon satisfaction of certain closing conditions including approval by Exicure stockholders, existing investor CBI USA, Inc. will purchase an aggregate of 3,400,000 shares of common stock for an aggregate purchase price
